CU24312B1 - Métodos para controlar los niveles de fucosilación en proteínas - Google Patents

Métodos para controlar los niveles de fucosilación en proteínas

Info

Publication number
CU24312B1
CU24312B1 CUP2016000008A CU20160008A CU24312B1 CU 24312 B1 CU24312 B1 CU 24312B1 CU P2016000008 A CUP2016000008 A CU P2016000008A CU 20160008 A CU20160008 A CU 20160008A CU 24312 B1 CU24312 B1 CU 24312B1
Authority
CU
Cuba
Prior art keywords
proteins
fucosilation
levels
methods
control
Prior art date
Application number
CUP2016000008A
Other languages
English (en)
Other versions
CU20160008A7 (es
Inventor
Laxmi Adhikary
Dinesh Baskar
Ankur Bhatnagar
Saravanan Desan
Ramakrishnan Melarkode
Casimiro Jose Enrique Montero
Pradip Nair
Haris Venkatraman Pai
Sunaina Prabhu
Kriti Shukla
Rasika Venkataraman
Original Assignee
Biocon Ltd
Centro De Inmunología Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd, Centro De Inmunología Molecular filed Critical Biocon Ltd
Publication of CU20160008A7 publication Critical patent/CU20160008A7/es
Publication of CU24312B1 publication Critical patent/CU24312B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

<p>La presente invención se relaciona con un método o procedimiento para controlar, inhibir o reducir la fucosilación de proteínas en un eucariota y/o sistema de expresión de proteínas eucariota. Dicho método comprende llevar a cabo la expresión de proteína y/o modificación post-traduccional en presencia de una elevada concentración de manganeso o de iones de manganeso.</p>
CUP2016000008A 2013-07-23 2014-07-23 Métodos para controlar los niveles de fucosilación en proteínas CU24312B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3265CH2013 2013-07-23
IN3262CH2013 2013-07-23
PCT/IB2014/063348 WO2015011660A1 (en) 2013-07-23 2014-07-23 Methods for controlling fucosylation levels in proteins

Publications (2)

Publication Number Publication Date
CU20160008A7 CU20160008A7 (es) 2016-11-29
CU24312B1 true CU24312B1 (es) 2018-02-08

Family

ID=52392808

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2016000008A CU24312B1 (es) 2013-07-23 2014-07-23 Métodos para controlar los niveles de fucosilación en proteínas

Country Status (19)

Country Link
US (2) US9856502B2 (es)
EP (2) EP3024922A4 (es)
JP (1) JP6480926B2 (es)
KR (1) KR102062784B1 (es)
CN (1) CN105392878A (es)
AU (1) AU2014294618B2 (es)
BR (1) BR112016001461A2 (es)
CA (1) CA2926967C (es)
CU (1) CU24312B1 (es)
EA (1) EA201690269A1 (es)
HK (1) HK1220228A1 (es)
MX (1) MX2016001042A (es)
NZ (1) NZ716182A (es)
PE (1) PE20160218A1 (es)
PH (1) PH12016500158A1 (es)
SG (1) SG11201600067YA (es)
TW (1) TWI621711B (es)
WO (1) WO2015011660A1 (es)
ZA (1) ZA201601113B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524233B2 (en) 2008-03-14 2013-09-03 Biocon Limited & Centro de Immunologia Molecular Monoclonal antibody and a method thereof
WO2016089919A1 (en) * 2014-12-01 2016-06-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
DK3529274T3 (da) * 2016-10-21 2024-06-17 Biocon Ltd Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus
EP3541835A4 (en) * 2016-11-18 2020-08-05 Biocon Limited FAST AND EFFICIENT ENTGLYCOSYLATION OF GLYCOPROTEINS
US20210079065A1 (en) * 2018-03-26 2021-03-18 Amgen Inc. Total afucosylated glycoforms of antibodies produced in cell culture
CA3107038A1 (en) * 2018-08-10 2020-02-13 Genentech, Inc. Cell culture strategies for modulating protein glycosylation
HUP1800376A2 (hu) 2018-11-07 2020-05-28 Richter Gedeon Nyrt Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
CN113015805A (zh) 2018-11-13 2021-06-22 詹森生物科技公司 抗cd38抗体产生期间的痕量金属的控制
JP7469593B2 (ja) 2018-12-27 2024-04-17 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体を製造する方法
CN112779307B (zh) * 2021-01-11 2022-04-19 苏州药明生物技术有限公司 一种两阶段调节cho表达外源蛋白糖型的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP2001523956A (ja) * 1997-03-03 2001-11-27 ブリストル−マイヤーズ・スクイブ・カンパニー ヒトｃｄ６に対するモノクローナル抗体
DE60301953T2 (de) 2002-03-05 2006-07-27 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
AU2006255085A1 (en) 2005-06-03 2006-12-14 Genentech, Inc. Method of producing antibodies with modified fucosylation level
AU2006324163B2 (en) 2005-12-08 2013-05-02 Amgen Inc. Improved production of glycoproteins using manganese
US7846724B2 (en) * 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US8524233B2 (en) * 2008-03-14 2013-09-03 Biocon Limited & Centro de Immunologia Molecular Monoclonal antibody and a method thereof
US20120277165A1 (en) * 2009-06-05 2012-11-01 Collins Brian E Methods of modulating fucosylation of glycoproteins
MX2012011648A (es) * 2010-04-07 2012-11-29 Momenta Pharmaceuticals Inc Glicanos de alta manosa.
US10059770B2 (en) * 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition

Also Published As

Publication number Publication date
EP3024922A4 (en) 2017-03-29
KR102062784B1 (ko) 2020-01-07
MX2016001042A (es) 2017-01-05
TW201512396A (zh) 2015-04-01
EP3024922A1 (en) 2016-06-01
WO2015011660A1 (en) 2015-01-29
BR112016001461A2 (pt) 2017-08-29
SG11201600067YA (en) 2016-02-26
AU2014294618A1 (en) 2016-02-11
CA2926967C (en) 2020-12-08
EA201690269A1 (ru) 2016-05-31
KR20160036589A (ko) 2016-04-04
ZA201601113B (en) 2017-08-30
JP2016525352A (ja) 2016-08-25
PH12016500158A1 (en) 2016-04-25
HK1220228A1 (zh) 2017-04-28
US10308970B2 (en) 2019-06-04
US20160138065A1 (en) 2016-05-19
US20180087080A1 (en) 2018-03-29
NZ716182A (en) 2018-07-27
EP4282975A2 (en) 2023-11-29
EP4282975A3 (en) 2024-02-28
PE20160218A1 (es) 2016-05-09
CN105392878A (zh) 2016-03-09
JP6480926B2 (ja) 2019-03-13
US9856502B2 (en) 2018-01-02
AU2014294618B2 (en) 2019-06-27
TWI621711B (zh) 2018-04-21
CA2926967A1 (en) 2015-01-29
CU20160008A7 (es) 2016-11-29

Similar Documents

Publication Publication Date Title
CU24312B1 (es) Métodos para controlar los niveles de fucosilación en proteínas
BR112018004887A2 (pt) sistemas e métodos de controle de potência.
EP3028100A4 (en) Application specific, dual mode projection system and method
BR112013032042A2 (pt) dispositivos e métodos de recepção e de difusão, programa, sistema de controle do aplicativo de ligação
BR112013032215A2 (pt) método e sistema para processamento de consultas de saldo de contas financeiras
BR112014029884A2 (pt) sistemas de controle e método.
EP2978559A4 (en) Laser welding system and method
BR112013032183A2 (pt) sistema e método de avaliação de recursos
EP2984346A4 (en) Water booster control system and method
WO2014197885A3 (en) Inhibitors of complement factor h
MX2015012428A (es) Tratamiento contra enfermedades mediadas th2 por inhibicion de bromodominios.
CL2016000021A1 (es) Combinación herbicida que comprende ácido pelargónico e inhibidores específicos de als
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
EP3066270A4 (en) Sewer system, and method of controlling it
JOP20210010A1 (ar) بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
EP3234887A4 (en) Intelligent system and method of payment, finance, and social commerce
EP3018756A4 (en) Tracking system, tracking method, and program
HK1221514A1 (zh) 對通電眼科鏡片進行編程的系統和方法
EP2959462A4 (en) Automated beverage generating system and method of operating the same
EP3088411A4 (en) Method for purifying antibody having low isoelectric point
WO2014130741A3 (en) Nme inhibitors and methods of using nme inhibitors
EP3335825A4 (en) INVISIBLE LASER SYSTEM AND LIGHT PATH VISIBLE PROCESS FOR THIS
CL2015002080A1 (es) Métodos de control selectivo de malezas
EP2991222A4 (en) Switching amplifier and control method therefor
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.